Venaxis (APPY) Acquires BiOptix
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Venaxis®, Inc. (Nasdaq: APPY), announced today that it has acquired BiOptix Diagnostics, Inc., ("BiOptix") a Boulder, CO-based privately-held company. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance ("E‑SPR") technology platform for the detection of molecular interactions. The technology was developed in conjunction with Dr. John 'Jan' Hall, Adjoint Professor, JILA (University of Colorado), who shared the Nobel Prize for Physics in 2005.
Venaxis acquired as of September 12, 2016, approximately 98% of the voting shares of BiOptix for approximately 14% of the Venaxis post-deal outstanding common shares.
BiOptix offers an affordable and powerful solution for drug discovery scientists that require label-free real-time detection of biomolecular interactions. The BiOptix unique enhanced instrumentation offers precise measurement of kinetics, affinity constants and concentration, proprietary easy-to-use analytical software, and two operating modes for higher throughput and experimental flexibility.
BiOptix' technology is an ultra-sensitive detection Surface Plasma Resonance (SPR) platform which combines high sensitivity with microarray detection capability allowing Pharma and Biotech researchers to understand much earlier in the discovery process whether their target molecules have functionality against the disease targeted. BiOptix' partners with academic research institutions, biotechnology, pharmaceutical, and contract research organizations to help make these partners drug development process more effective and productive.
SPR is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants.
"We are pleased to announce this acquisition and are excited by the opportunity we believe it represents for shareholders of Venaxis," said Steve Lundy, Chief Executive Officer of Venaxis, Inc. "The newly combined company will benefit from BiOptix technology and market opportunity, combined with Venaxis resources and public listing. The company is expected to initially focus on product improvement initiates and expanding commercialization of BiOptix's 404pi E-SPR product."
Conference Call Venaxis will host an investor conference call to discuss the transaction on Wednesday, September 14, 2016, at 8:45 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO of Venaxis, Inc.
A live audio webcast will be accessible via the Investor Relations section of the Venaxis website, www.venaxis.com. Participants and investors may also access the conference call by dialing 1-888-283-6901 (U.S.) or 1-719-457-2506 (Toll – International).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concordia International (CXRX) CEO to Step Down
- Monster Worldwide (MWW) Issues Response to MediaNews Group; Says Offer Would be 'Far Less' than Randstad's
- EU regulators want to know if LinkedIn data is unique: sources
Create E-mail Alert Related CategoriesCorporate News, Management Comments, Mergers and Acquisitions
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!